|Videos|December 16, 2022

The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel

Author(s)Neal Shore, MD, FACS

Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.

Episodes in this series

EP. 1 Case Presentation: A 74-Year-Old Man With Metastatic Prostate Cancer

EP. 1 Case Presentation: A 74-Year-Old Man With Metastatic Prostate Cancer

EP. 2 Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP. 2 Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP. 3 Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA Trials

EP. 3 Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA Trials

EP. 4 Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial

EP. 4 Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial

EP. 5 Factors for Consideration When Selecting Patients with mCRPC for Treatment With Cabazitaxel

EP. 5 Factors for Consideration When Selecting Patients with mCRPC for Treatment With Cabazitaxel

EP. 6 Selecting Between Treatment With Cabazitaxel or Radiotherapy for Patients with mCRPC

EP. 6 Selecting Between Treatment With Cabazitaxel or Radiotherapy for Patients with mCRPC

EP. 7 The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel

EP. 7 The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel

EP. 8 Unmet Needs and Clinical Pearls in mCRPC

EP. 8 Unmet Needs and Clinical Pearls in mCRPC

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

ByLorelei A. Mucci, ScD, MPH

September 11th 2026

Doublet or triplet? Urologists weighs in on mCSPC options

ByUrology Times staff

September 10th 2026

Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD

ByMartin Schoen, MD, PhD,Hannah Clarke

September 10th 2026

App-based intervention aims to increase PSA screening among Black men

ByHannah Clarke

September 9th 2026

The critical role of advocacy in urologic oncology

ByRuchika Talwar, MD,Lan Anh Galloway, MD

September 9th 2026

Latest CME

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Alternative BCG strains may help address ongoing supply challenges in NMIBC

Doublet or triplet? Urologists weighs in on mCSPC options

Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

Phase 3 trial of padeliporfin VTP completes treatment in LG-UTUC